Sano T, Naito T, Kubo T (eds).

[Medicinal Chemistry, an Introduction (7th ed)] (In Japanese)

Nankodo (2002)

Fukai S.

[New Drugs Today (6th ed)] (In Japanese)

Jiho (1995)

Tanaka C, Kato R (eds).

[New Pharmacology (4th ed)] (In Japanese)

Nankodo (2002)

Guldberg HC, Marsden CA.

Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Pharmacol Rev 27:135-206 (1975)

Micek ST, Ernst ME.

Tolcapone: a novel approach to Parkinson's disease.

Am J Health Syst Pharm 56:2195-205 (1999)
DOI:10.1093/ajhp/56.21.2195

.

Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.

Prescrire Int 15:54-7 (2006)

Kaakkola S, Gordin A, Mannisto PT.

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.

Gen Pharmacol 25:813-24 (1994)
DOI:10.1016/0306-3623(94)90082-5

Tornwall M, Mannisto PT.

Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.

Eur J Pharmacol 250:77-84 (1993)
DOI:10.1016/0014-2999(93)90623-P

Youdim MB, Gross A, Finberg JP.

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Br J Pharmacol 132:500-6 (2001)
DOI:10.1038/sj.bjp.0703826

Youdim MB, Bakhle YS.

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

Br J Pharmacol 147 Suppl 1:S287-96 (2006)
DOI:10.1038/sj.bjp.0706464

Mannisto PT, Kaakkola S.

Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Pharmacol Rev 51:593-628 (1999)